期刊文献+

注射用醋酸艾塞那肽缓释微球的制备及体外释药研究 被引量:1

Study on the preparation and release in vitro of Exenatide Acetate Sustained-releasing Microspheres for injection
暂未订购
导出
摘要 目的制备注射用醋酸艾塞那肽缓释微球,以达到缓释作用,从而减少用药次数。方法以聚乳酸-羟基乙酸为载体,羧甲基纤维素钠水溶液为分散介质,乙酸乙酯为有机溶剂,甘露醇为保护剂,通过复乳-液中干燥法和冷冻干燥法制备注射用醋酸艾塞那肽缓释微球。以微球收率、粒径、包封率为指标,采用正交试验法来优化微球的处方和制备工艺。采用透析法考察含药微球的体外释药特性,计算微球累积释药百分率,绘制体外释药曲线。结果通过正交设计筛选出制备注射用醋酸艾塞那肽缓释微球的处方和制备工艺,载药量为21.3%,包封率为94.6%,Zeta电位为(-29.3±1.51)mV,含药缓释微球的体外释药过程符合Higuchi方程。结论制备的注射用醋酸艾塞那肽缓释微球具有30 d的缓释效果。 Objective To prepare Exenatide Acetate Sustained-release Microspheres to realize the sustained-release effect and reduce the frequency of drug use. Methods Exenatide Acetate Sustained-release Microspheres were prepared by the method of double-elusion drying in liquid with PLGA as the carrier, ethyl acetate as the organic solvent, CMC-Na water solution as the dispersion medium and mannitol as the diluents and the method of freezing drying.The prescription and preparation process were optimized by orthogonal test with particle size,yield and encapsulation as the investigating index.The property of releasing drug in vitro was investigated by the method of dialysis.The cumulative drug-releasing percentage of Sustained-release Microspheres was calculated and the drug-releasing curve was drawn. Results The prescription and preparation process were screened according to the orthogonal test with a drug loading capacity of 21.3%,an encapsulation efficiency of 94.6% and a Zeta potential of (-29.3+1.51) mV.The releasing profile in vitro was in accordance with Higuchi equation. Conclusion The Exenatide Acetate Sustained-release Microspheres for injection have releasing effect of 30 days.
出处 《中国当代医药》 2015年第27期10-13,共4页 China Modern Medicine
关键词 醋酸艾塞那肽 缓释微球 体外释放 Exenatide Acetate Sustained-release Microspheres Release in vitro
  • 相关文献

参考文献18

  • 1许玲美,徐智儒,檀琼,肖峰,赵莎莎,秦燕.2型糖尿病治疗药物艾塞那肽及其开发[J].世界临床药物,2013,34(7):427-430. 被引量:3
  • 2侯书杰,才丽,李克剑,孙欧希.GLP-1类似物艾塞那肽研究进展[J].中国执业药师,2013,10(7):38-39. 被引量:14
  • 3刘延杰,季虹,林鲁霞,荣海钦.艾塞那肽的抗糖尿病机制及临床应用进展[J].中国新药与临床杂志,2011,30(6):407-411. 被引量:9
  • 4Blonde L, Klein E, Han J, et al.Interim analysis of the ef- fects of exenatide treatment on AIC,weight and cardiovas- cular risk factors over 82 weeks in 314 overweight pa- tients with type 2 diabetes[J].Diabetes Obes Metab,2006, 8(4) :436-447.
  • 5Best JH,Hoogwerf BJ,Herman WH,et al.Risk of cardio- vascular disease event in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies : a retrospective analysis of the life link database [J].Diabetes Care, 2011,34( 1 ) : 90-95.
  • 6Klonoff DC,Buss JB,Nielsen LL,et al.Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepat- ic biomarkers in patients with type 2 diabetes treated for at least 3 years[J].Curr Med Res Opin, 2008,24(1):275- 286.
  • 7Mehta RC,Jeyanthi R, Calls S,et d.Biodegradable micro-spheres as depot system for patenteral delivery of peptide drugs[J].J Control Release, 1994,29(3) : 375-384.
  • 8Jiang W,Gupta RK, Deshpande MC,et al.Biodegradable poly(lactic-co-glycolic acid) mieroparticles for injectable delivery of vaccine antigens[J].Advan Drug Delivery Rev, 2005,57(3) : 391-410.
  • 9Nair LS,Laurencin CT.Biodegradable polymers as bioma- terials[J].Prog Polym Sci, 2007,32 (8-9) : 762-798.
  • 10丁里玉,夏鹏飞,杨彩琴,林玉龙,王静.血竭聚乳酸缓释微球的制备及体外释药研究[J].中国中药杂志,2007,32(5):388-390. 被引量:5

二级参考文献137

共引文献50

同被引文献11

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部